- Home
- LH vs MRNA Comparison
LH vs MRNA Comparison
Compare LH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | MRNA |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 21.6B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LH | MRNA |
|---|---|---|
| Price | $255.36 | $63.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 12 |
| Target Price | ★ $311.33 | $34.27 |
| AVG Volume (30 Days) | 512.3K | ★ 6.0M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | 18.33 | ★ 21.77 |
| EPS | ★ 3.35 | N/A |
| Revenue | $13,951,700,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $8.26 | $9.36 |
| Revenue Next Year | $4.81 | $15.43 |
| P/E Ratio | $76.33 | ★ N/A |
| Revenue Growth | ★ 7.25 | 4.29 |
| 52 Week Low | $241.81 | $22.28 |
| 52 Week High | $293.72 | $67.74 |
Technical Indicators
Market Signals| Indicator | LH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 75.16 |
| Support Level | $248.61 | $45.69 |
| Resistance Level | $274.48 | N/A |
| Average True Range (ATR) | 5.90 | 3.88 |
| MACD | -0.43 | 1.81 |
| Stochastic Oscillator | 12.60 | 85.43 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.